J&J opts out of licensing Genmab’s Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. | Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody,
Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...
Genmab (GMAB) reported strong Q4 2024 results last week and provided 2025 revenue guidance that was slightly ahead of the Street consensus and expense guidance that was below expectations.
Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation ...
We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...
Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year. Genmab A/S Company ...
Morgan Stanley says intra-day pressure on Genmab (GMAB) of greater than 5% after Genmab announced that partner Johnson & Johnson (JNJ) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback